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Abstract 
Background: For patients with a thoracic malignancy whose peripheral veins are not 
suitable for blood access for chemotherapy, we evaluated a totally implantable central 
venous access port, in which the port is implanted in the ulnar side of arm and the 
catheter is introduced via the basilic vein into the superior vena cava (TIAP-BV).  
Methods: Twenty-five patients (21 with lung cancer, 2 with malignant pleural 
mesothelioma, and 2 with thymoma) receiving TIAP-BV were included. Indication, 
surgical complications, and long-term complications were analyzed.  
Results: Indications for TIAP-BV were: chemotherapy (17 patients); chemotherapy 
with parenteral nutrition (8 patients). The following surgical complications occurred: 
arrhythmia due to misplacement of the tip of catheter (1 patient); intraoperative 
conversion from the left to right arm (2 patients); hematoma at the implantation site (1 
patient). Short-term problems were: death 1 week after implantation without the use 
of TIAP-BV (2 patients). Long-term complications were: skin ulcer at the port site (1 
patient); early removal of TIAP-BV because of port site infection (1 patient); catheter 
occlusion (1 patient); venous thrombosis of basilic vein (2 patients). In the 22 patients 
who did not die early or have the device withdrawn early, the median duration of 
TIAP-BV use was 7 months (range, 1 to 20) without any break to the port system, 
leakage of drugs, or catheter-related infections.  
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Conclusion: TIAP-BV can endure the long-term use for chemotherapy and 
parenteral nutrition. However, a patient’s expected prognosis and infectious disease 
status at time of implantation surgery should be considered before surgery proceeds.  
 
Mini-abstract 
We present on the safety of the implantation and use of implantable venous port via 




Totally implantable central venous access port, basilic vein, lung cancer
4 / 26 
Text 
Introduction 
In lung cancer chemotherapy, third-generation chemotherapeutic drugs 
(paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) have been 
associated with significant advances in survival benefit and improvement in the 
quality of life1, with platinum-based regimens the first choice. Third-generation 
monotherapy, as well as new drugs such as amrubicin or pemetrexate, are 
considered good candidates for second / third-line regimens2; in malignant pleural 
mesothelioma and invasive thymoma, several complex but effective regimens have 
been reported3, 4. Therefore, patients with advanced thoracic malignancy frequently 
require repeated puncture of peripheral veins for blood tests, administration of 
consecutive chemotherapeutic agents, fluid administration, and occasionally 
parenteral nutrition over a long period of time.  
During repeated puncture of peripheral veins, oncology practitioners 
sometimes encounter patients with peripheral veins no longer able to accept an 
indwelling needle. A consequence of this is that medical oncologists will not be able 
to find a reliable peripheral vein for administering the chemotherapeutic drugs that 
have a high potential for the induction of skin necrosis due to extravasation, such as 
vinorelbine5, docetaxel, paclitaxel, and amrubicin.  
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For easy, safe and repeated venous access, totally implantable central 
venous access ports (TIAP), are widely used for the safe administration of 
chemotherapeutic drugs, blood transfusion and parenteral nutrition in oncology; these 
devices can also facilitate the problem of the venous access in thoracic 
malignancies6.  
For the placement of a TIAP, catheter introduction through the subclavian 
vein to the superior vena cava (SVC) via the percutaneous approach, is the most 
common technique6, 7. However, this approach via the subclavian vein is associated 
with considerable complications including pneumothorax, hemothorax, injury of large 
vessels, and catheter pinch-off within the costclavicular space6-8. The venous 
cut-down approach through the external jugular vein or cephalic vein has been 
reported to be one of a number of safe and easy alternatives9-11.  
In our department, prior to May 2006, we used the ‘TIAP via subclavian vein’ 
approach. However, with this method, we experienced two cases of pinch-off 
syndrome of the implanted catheter. From June 2006, therefore, we have used the 
TIAP with the port implanted in the ulnar side of the arm, and the catheter introduced 
via the basilic vein to the SVC (TIAP-BV), using the Seldinger method. We made this 
switch due to the easier technique for implantation compared to the cut-down 
approach, and the avoidance of pinch-off of the catheter. Herein, we report our 
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experiences and problems associated with the use of TIAP-BV.  
 
Patients and methods 
Patients 
This was a retrospective study in 25 patients with thoracic malignancy; all 
patients had peripheral veins that were too fragile for practitioners to insert the usual 
indwelling needles for chemotherapy and/or fluid administration. Between June 2006 
and December 2007, these 25 patients underwent implantation of TIAP-BV in which 
the port was implanted in the ulnar side of arm and the catheter was introduced via 
the basilic vein to the SVC, because of the fragility of their peripheral veins.  
Implantation procedures of TIAP-BV 
Implantation surgery was performed at the outpatient surgery unit of our 
hospital. Prior to the procedure, the direction of the basilic vein in the ulnar side of the 
arm (usually the left one) was established using radiographic or ultrasonographic 
guidance (Figure 1). For left-handed patients, the right arm was selected. Under local 
anesthesia, an approximately 4 cm long incision was made in the skin in the center of 
the ulnar side of arm and a subcutaneous pocket was prepared for the port body 
(Vital-Port MINI, IP-S5116, Cook Vascular Incorporated, Vandergrift, PA, USA) 
(Figure 2). The direction of the basilic vein was identified again during the operation 
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under venography. According to the Seldinger method, the basilic vein was 
punctured with 20 gauge indwelling needle under venograpy (Figure 3A and 
3B). And then a guide wire (Radifocus Guidewire M, RF-GA25123, Terumo Co. 
Ltd, Tokyo, Japan) was introduced through the basilic vein (Figure 3C) to the 
SVC. After dilating the puncture point of basilic vein with the introducer, a catheter 
was introduced along the guide wire and the tip of the catheter was placed in the 
SVC under radiographic guidance. The distal end of catheter was attached to the port 
body and the port was placed in the pocket. Flushing and filling with heparinized 
saline (100IU/ml) was performed to verify the flow through the port system.  
Use of TIAP-BV 
If no incidences of hematoma, infection, or serous fluid retention were 
identified during a period of 3 to 7 days after implantation, then the TIAP-BV was 
used. The medical staff who used the TIAP-BV were all well-trained staff physicians 
of the Outpatient Oncology Unit or the Department of Respiratory Medicine, or staff 
surgeons of the Department of Thoracic Surgery at our institute. For puncture of the 
port, a 22-gauge non-coring needle (Coreless Needle Set, Nipro Co. Ltd, Osaka, 
Japan) was used under aseptic conditions. After the TIAP-BV was used, it was 
flushed with 10ml of heparinized saline (100IU/ml). In patients with a temporary 
interruption of their chemotherapy, heparin flushing of the TIAP-BV was performed at 
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intervals of approximately 4-week intervals. 
  
Evaluation 
The reason for the implantation of the TIAP-BV, the number of regimens and 
cycles of chemotherapy before and after implantation, the operation time, 
complications of implantation surgery, usage of the TIAP-BV, and long-term 
complications / problems that occurred during the period from the implantation to 
April 2008, were all evaluated. Continuous variables were expressed as medians and 
the range given.  
 
Results 
Patient demographics and baseline characteristics are presented in Table 1. 
Of 25 patients, 14 were male and 11 were female; they had a median age of 66 years 
(range, 39 - 79 years). Twenty-one patients had lung cancer, two had malignant 
pleural mesothelioma, and two had invasive thymoma.  
The reasons for the use of TIAP-BV were: chemotherapy (17 patients) and 
chemotherapy with parenteral nutrition (8 patients). The median duration from the 
beginning of chemotherapy to implantation of TIAP-BV was 18 months (range, 0 to 
84 months). The median number of chemotherapeutic regimens and cycles 
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prior to TIAP-BV implantation was 2 (range, 0 to 11) and 8 (range, 0 to 46), 
respectively.  
We planned initially to place the TIAP-BV on the left side in 24 patients, and 
on the right side in one. A left-sided placement was successful in 22 of the 24 
patients as planned; in the other 2 patients it became necessary to convert to the 
right because the left basilic vein was too fragile to insert a dilating introducer. The 
right-sided placement was also successful in the one patient in whom the intention 
had always been to opt for this side. The median time for the implantation was 37 
minutes (range, 27 to 120 minutes).  
With respect of surgical complications (Table 2), arrhythmia (frequent 
paroxysmal atrial contraction) occurred in 1 patient, probably as a consequence of 
the tip of catheter touching the right atrium. After replacing the catheter tip on the 
SVC, the arrhythmia disappeared. In addition, a hematoma at the implanted site was 
reported in another patient, which resolved within 2 weeks. With respect of immediate 
mortality and morbidity problems (Table 2), 2 patients (8%) died, within 1 week of 
implantation, before a TIAP-BV had been used, because of a rapid disease 
progression. In 1 (4%) other patient, early removal of the TIAP-BV occurred, 8 days 
after implantation because of a port site infection, secondary to aspiration pneumonia 
with bacteremia due to methicillin-resistant Staphylococcus aureus.  
10 / 26 
With respect of long-term complications (Table 2), venous thrombosis of the 
basilic vein in which the catheter was placed was observed in 2 (8%) patients, 
approximately 3 weeks after implantation. These 2 patients received warfarin 
treatment and their TIAP-BV continued to be used without further complications, 
including pulmonary thromboembolism. Skin ulcer at the port site due to cutting of 
skin with needle during repeated puncture was observed in one patient (4%) after 
7 months of use for chemotherapy and parenteral nutrition. Port occlusion was 
documented in one patient (4%) after 5 months of use for chemotherapy and 
parenteral nutrition. Among the 22 patients who were free of short-term complications 
(ie early death or early removal of the TIAP-BV), the TIAP-BV were used for a 
median of 7 months (range, 1 to 20 months) without damage to the port or catheter, 
leakage of drugs outside of the port system, pinch-off syndrome, or catheter-related 
infections. Of these 22 patients, 3 received none of their planned intravenous 
chemotherapy, but their TIAP-BVs were effectively used for parenteral nutrition 
or fluid administration. In the other 19 patients, the median number of 
chemotherapeutic regimens and cycles after TIAP-BV implantation was 2 
(range, 1 to 3) and 9 (range, 1 to 21), respectively. As of April 2008, 10 out of 25 
patients (40%) had died since the placement of a TIAP-BV.  
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Discussion 
In this paper, we evaluated the experiences and the problems in the use of 
TIAP-BV in thoracic malignancy, because we had been aware that there were very 
few reports on the use of TIAP in the Japanese population or regarding the 
implantation approach through the basilic vein with the Seldinger method.  
In our patient series, the median of chemotherapeutic regimens prior to 
TIAP-BV implantation was 2, consisting of 8 cycles in median. Currently, there is 
no definitive indication for timing the employment of TIAP in the treatment of thoracic 
malignancies. In our institute, docetaxel- or vinorelbine-containing regimens are 
frequently used as second-line regimens for lung cancer and the peripheral veins of 
patients occasionally become fragile during second-line chemotherapy. In this 
situation, subsequent administration of third-line chemotherapy containing irinotecan, 
gemcitabine, or amrubicin through the peripheral veins carries a high risk for the 
development of skin ulcers and necrosis due to extravasation of drugs. Therefore, 
maybe the beginning of third-line regimen with potentially necrosis-inducing agents 
would be timely for the placement of TIAP.  
With respect to surgical complications, we experienced two cases requiring 
intraoperative conversion from the left to right basilic vein. In both cases, we had 
ascertained a good flow through the left basilic vein immediately before surgery using 
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venography or ultrasonography. However, intra-operation findings indicated that the 
walls of the basilic veins in these 2 patients were very fragile and considerable blood 
leakage occurred at the point of puncture for the wire guiding. Therefore, we decided 
to switch to the right arm. Conversion to the cut-down method involving the cephalic 
vein at a more central portion such as the delto-pectoral groove may be good 
alternative9 in these situations.  
Arrhythmia and hematoma were also documented as surgical complications 
in our patient series. These would appear to be avoidable with careful catheter 
placement or hemostasis ascertainment.  
Two early deaths were observed after implantation of TIAP-BV; both deaths 
were unrelated to TIAP-BV implantation, and due to disease progression. 
Furthermore, in neither patient had the TIAP-BVs been used for chemotherapy or 
fluid administration prior to death. Sadly, this means that for these 2 patients the 
implantation surgery had been in vain. This highlights the need for a careful 
evaluation of the prognosis of all potential candidates for TIAP-BV, prior to the 
procedure being started.  
Catheter-related Infection is one important potential complication in the 
long-term management of TIAP. In the literature, infections related to totally 
implantable port systems occurred in 2.0% to 9.1% of patients12-15. In our series, 
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although no catheter-related infections in the long-term management of TIAP-BV 
were observed, one early port site infection due to bacteremia from aspiration 
pneumonia occurred immediately after implantation surgery was documented. This 
patient was aspiration-prone and easily developed bacteremia such as the one that 
caused this episode of catheter and port infection. Because the hematogenous 
infection of TIAP cannot be avoided, even with the strictest antiseptic procedures 
being followed during the puncture of the port, severely compromised patients 
including aspiration-prone patients or patients with an active infection should not be 
considered for implantation.  
Thromboembolic complication is another important potential problem in the 
long-term management of TIAP. Catheter implantation itself carries a risk for venous 
thrombosis and cancer patients who need a TIAP have an increased risk of venous 
thrombosis6, 16. Although the detailed incidence of thromboembolic complications in 
TIAP-BV that we use is unclear, Kuriakose et al. reported that a higher incidence of 
arm venous thrombosis in patients with a peripherally placed port (11.4%) than with a 
chest port (4.8%)17. The incidence of arm venous thrombosis in our series (8%) is 
compatible to that of peripherally placed port. There are currently no definite 
recommendations or guidelines for the use of prophylactic anticoagulation therapy to 
prevent thromboembolic complications regarding TIAP6. Therefore, we feel that the 
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prompt use of anticoagulation therapy after the occurrence of venous thrombosis is 
essential16.  
No complications regarding a breakdown of the port system or drug leaks 
were observed over the period of 1 to 20 months used in our series. This is probably 
because the main users of TIAP-BV at our institute were all highly trained in the use 
of several types of TIAP systems, including TIAP-BV, and thereby mechanical 
damage to the port system could be avoided. Like other types of TIAP, TIAP-BV can 
provide safe venous access for long-term use when used appropriately by trained 
practitioners.  
In conclusion, for patients with peripheral veins no longer able to accept an 
indwelling needle, TIAP-BV is safe and suitable for the long-term use of 
chemotherapy, fluid administration, and parenteral nutrition in thoracic malignancy. 
Even from our limited experience, however, early death of patients and early 
removal after implantation are the most problematic waste use in application of 
TIAP-BV. Therefore, in considering the indication for the procedure, we should 
verify that a candidate of TIAP-PV has good performance status and organ 
functions enough to receive chemotherapy, has a certain level of prognosis 
when the chemotherapy would be effective, and has no active infection.  
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Table 1  Patient Characteristics and Baseline Demographics (N=25) 
      
  Number of 
    Patients 
Sex Male 14 
 Female 11 
   
Age (years) Median 66 
 Range 39 - 79 
   
Disease Lung cancer 21 
 Malignant pleural mesothelioma 2 
 Invasive thymoma 2 
   
Purpose of  Chemotherapy 17 
implantation Chemotherapy with parenteral nutrition 5 
   
Number of  0 regimen 1 
Regimens 1 regimen 4 
before implantation 2 regimens 8 
 3 regimens 5 
 4 regimens 5 
 5 regimens 1 
 11 regimens 1 
   
Number of  0 cycle 1 
Cycles 1 to 5 cycles 7 
before implantation 6 to 10 cycles 7 
 11 to 15 cycles 5 
 16 or more cycles 5 
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Table 2 Complications and problems  
      
  Number of 
    Patients 
Surgical Arrhythmia 1 
Complications Hematoma 1 
   
Short-term Early death without use of port 2 
Complications Port-site infection caused by bacteremia 1 
   
Long-term Venous thrombosis 2 
Complications Skin ulcer 1 
  Port occlusion 1 
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Figure Legends 
Figure 1 
After a contrast agent was injected, the direction of the left basilic vein was visualized 
under radioscopy. Arrowheads indicate the basilic vein.  
Figure 2 
A skin incision, approximately 4 cm long, and in a direction perpendicular to the 
running of the basilic vein, was made in the center of the ulnar side of the arm and a 
subcutaneous pocket was prepared for the port body.  
Figure 3 
According to the Seldinger method, a 20-gauge indwelling needle was inserted 
into the basilic vein (3A) under venography (3B) and a guide wire was 
introduced through the basilic vein (3C) to the SVC.  
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Figure 3B 
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Figure 3C 
